Why the study?
Hypertension creates an increasing health financing burden, and the variety of guideline-recommended first-line antihypertensive combinations highlights the importance of pharmacoeconomic studies to determine the most cost-effective option.
Does the combination of nifedipine and candesartan improve blood pressure reduction and reduce side effects compared to placebo or monotherapy in patients with hypertension?
Does the combination of nifedipine and candesartan improve blood pressure reduction and reduce side effects compared to placebo or monotherapy in patients with hypertension?
The combination of nifedipine and candesartan provides significant blood pressure reduction with a more favorable side effect profile compared to monotherapy, supporting its use as a potentially cost-effective treatment strategy for hypertension.
Hypertension drives rising health financing burdens; leaves open evaluation of preventive strategies to curb long-term costs.
Healthcare financing involves the management of various efforts to mobilize, allocate, and spend health funds to ensure the implementation of health development aimed at achieving the highest possible level of public health. Hypertension, a non-communicable disease (NCD) continues to evolve and poses a serious public health issue and leads to an increasing health financing burden. Health Social Security Agency (BPJS) indicated direct medical costs of hypertension IDR 3 trillion in 2017 and 2018. The variety of first-line antihypertensive combinations due to the numerous recommended first-line antihypertensive combinations in various guidelines highlights the importance of pharmacoeconomic studies to determine the most cost-effective combination. This review article aims to further discuss the implementation of the CEA method as a basis for treatment selection or decision-making regarding hypertension treatment. The nifedipine 60 mg and candesartan 32 mg combination is deemed the best, achieving a blood pressure reduction of 23,8/16,5 mmHg (p<0,01) compared to placebo and monotherapy reductions of 5,3/6,7 mmHg. Additionally, the nifedipine GITS - candesartan combination reduces vasodilator side effects incidence to 18,3% compared to 23,6% for nifedipine monotherapy, including a lower incidence of headaches (5,5% vs. 11%).
No takes yet. Share an insight, caveat, or question.
Nabilah et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: